Rodríguez-Antona C - Search Results

1

Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.

Rodríguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Rodríguez-Antona C, et al. Clin Pharmacol Ther. 2005 Apr;77(4):259-70. doi: 10.1016/j.clpt.2004.11.003. Clin Pharmacol Ther. 2005. PMID: 15903124

2

Transcriptional regulation of the human CYP2A6 gene.

Pitarque M, Rodríguez-Antona C, Oscarson M, Ingelman-Sundberg M. Pitarque M, et al. J Pharmacol Exp Ther. 2005 May;313(2):814-22. doi: 10.1124/jpet.104.081570. Epub 2005 Jan 25. J Pharmacol Exp Ther. 2005. PMID: 15671201

3

A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.

Rodriguez-Antona C, Axelson M, Otter C, Rane A, Ingelman-Sundberg M. Rodriguez-Antona C, et al. J Biol Chem. 2005 Aug 5;280(31):28324-31. doi: 10.1074/jbc.M502309200. Epub 2005 Jun 2. J Biol Chem. 2005. PMID: 15937338 Free article.

4

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Ingelman-Sundberg M, Rodriguez-Antona C. Ingelman-Sundberg M, et al. Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1563-70. doi: 10.1098/rstb.2005.1685. Philos Trans R Soc Lond B Biol Sci. 2005. PMID: 16096104 Free PMC article. Review.

5

Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.

Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Rodríguez-Antona C, et al. Biochem Biophys Res Commun. 2005 Dec 9;338(1):299-305. doi: 10.1016/j.bbrc.2005.09.020. Epub 2005 Sep 13. Biochem Biophys Res Commun. 2005. PMID: 16171783

6

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Ingelman-Sundberg M, et al. Pharmacol Ther. 2007 Dec;116(3):496-526. doi: 10.1016/j.pharmthera.2007.09.004. Epub 2007 Oct 9. Pharmacol Ther. 2007. PMID: 18001838 Review.

7

A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.

Pitarque M, von Richter O, Rodríguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. Pitarque M, et al. Hum Mutat. 2004 Mar;23(3):258-66. doi: 10.1002/humu.20002. Hum Mutat. 2004. PMID: 14974084

8

Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).

von Richter O, Pitarque M, Rodríguez-Antona C, Testa A, Mantovani R, Oscarson M, Ingelman-Sundberg M. von Richter O, et al. Pharmacogenetics. 2004 Jun;14(6):369-79. doi: 10.1097/00008571-200406000-00006. Pharmacogenetics. 2004. PMID: 15247629

9

Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.

Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M. Rodríguez-Antona C, et al. Pharmacogenomics J. 2008 Aug;8(4):268-77. doi: 10.1038/sj.tpj.6500482. Epub 2007 Oct 9. Pharmacogenomics J. 2008. PMID: 17923851

10

New approaches and applications in chemical biology.

Gomez A, Ingelman-Sundberg M, Johansson I, Karlgren M, Rodriguez-Antona C, Sim SC. Gomez A, et al. Drug News Perspect. 2004 Nov;17(9):594-605. Drug News Perspect. 2004. PMID: 15645017

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters